BR112014026744A2 - anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, métodos para tratar uma condição, distúrbio ou doença, para modular um distúrbio ou condição e para produzir um anticorpo ou fragmento, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada - Google Patents

anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, métodos para tratar uma condição, distúrbio ou doença, para modular um distúrbio ou condição e para produzir um anticorpo ou fragmento, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada

Info

Publication number
BR112014026744A2
BR112014026744A2 BR112014026744A BR112014026744A BR112014026744A2 BR 112014026744 A2 BR112014026744 A2 BR 112014026744A2 BR 112014026744 A BR112014026744 A BR 112014026744A BR 112014026744 A BR112014026744 A BR 112014026744A BR 112014026744 A2 BR112014026744 A2 BR 112014026744A2
Authority
BR
Brazil
Prior art keywords
antibody
fragment
disorder
condition
composition
Prior art date
Application number
BR112014026744A
Other languages
English (en)
Other versions
BR112014026744A8 (pt
Inventor
Frey Gerhar
Wen Chang Hwai
Short Jay
Boyle William
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of BR112014026744A2 publication Critical patent/BR112014026744A2/pt
Publication of BR112014026744A8 publication Critical patent/BR112014026744A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1 / 1 resumo “anticorpo isolado ou fragmento de anticorpo, composiã‡ãƒo de anticorpo ou composiã‡ãƒo de fragmento de anticorpo, mã‰todos para tratar uma condiã‡ãƒo, distãšrbio ou doenã‡a, para modular um distãšrbio ou condiã‡ãƒo e para produzir um anticorpo ou fragmento, dispositivo mã‰dico, formulaã‡ãƒo, kit, artigo de fabricaã‡ãƒo para uso farmacãšutico humano, animal ou planta transgãšnica, e, anticorpo ou porã‡ãƒo ou variante especificada” anticorpos anti-cd22, incluindo ã¡cidos nucleicos isolados que codificam pelo menos um anticorpo anti-cd22 como este, vetores, cã©lulas hospedeiras, plantas ou animais transgãªnicos, e mã©todos de preparar e usar os mesmos, incluindo composiã§ãµes terapãªuticas, mã©todos e dispositivos.
BR112014026744A 2012-04-26 2013-04-26 anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, uso de modulação imune, uso de pelo menos uma composição de anticorpo ou fragmento de anticorpo, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, método para produzir um anticorpo ou fragmento, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada. BR112014026744A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261638834P 2012-04-26 2012-04-26
PCT/US2013/038370 WO2013163519A1 (en) 2012-04-26 2013-04-26 Anti-cd22 antibodies

Publications (2)

Publication Number Publication Date
BR112014026744A2 true BR112014026744A2 (pt) 2017-07-11
BR112014026744A8 BR112014026744A8 (pt) 2018-01-16

Family

ID=49483918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026744A BR112014026744A8 (pt) 2012-04-26 2013-04-26 anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, uso de modulação imune, uso de pelo menos uma composição de anticorpo ou fragmento de anticorpo, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, método para produzir um anticorpo ou fragmento, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada.

Country Status (12)

Country Link
US (2) US9856323B2 (pt)
EP (1) EP2841459A4 (pt)
JP (1) JP2015516984A (pt)
KR (1) KR20150008080A (pt)
CN (1) CN104428316A (pt)
AU (2) AU2013251482B2 (pt)
BR (1) BR112014026744A8 (pt)
CA (1) CA2871764A1 (pt)
HK (1) HK1207653A1 (pt)
MX (1) MX361533B (pt)
RU (1) RU2014147452A (pt)
WO (1) WO2013163519A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3728319A1 (en) 2017-12-22 2020-10-28 TeneoBio, Inc. Heavy chain antibodies binding to cd22
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2020252366A1 (en) 2019-06-14 2020-12-17 Teneobio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
WO2021083467A1 (en) * 2019-10-28 2021-05-06 Y-Mabs Therapeutics, Inc. Administration of cd22, cd33 and/or tim-3 antibodies using ommaya reservoirs for the treatment of cns cancer or neurodegenerative diseases
CA3177230A1 (en) * 2020-04-02 2021-10-07 Nanjing Iaso Biotherapeutics Co., Ltd. Fully human anti-human cd22 chimeric antigen receptor and application thereof
CN113527507A (zh) 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
WO2021250275A1 (en) * 2020-06-12 2021-12-16 Ichnos Sciences SA Antibody formulation diluent
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
AR127568A1 (es) 2021-11-03 2024-02-07 Affimed Gmbh Ligandos biespecíficos de cd16a

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195557C (en) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN103030696B (zh) 2006-05-30 2016-09-28 健泰科生物技术公司 抗体和免疫偶联物及其用途
ES2678060T3 (es) * 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
WO2014057118A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates

Also Published As

Publication number Publication date
JP2015516984A (ja) 2015-06-18
US20150086562A1 (en) 2015-03-26
WO2013163519A1 (en) 2013-10-31
US20180086843A1 (en) 2018-03-29
MX2014012977A (es) 2015-02-05
AU2013251482B2 (en) 2018-01-04
CA2871764A1 (en) 2013-10-31
US9856323B2 (en) 2018-01-02
AU2013251482A1 (en) 2014-10-30
MX361533B (es) 2018-12-07
BR112014026744A8 (pt) 2018-01-16
EP2841459A4 (en) 2016-04-13
HK1207653A1 (en) 2016-02-05
AU2017268687A1 (en) 2017-12-21
CN104428316A (zh) 2015-03-18
RU2014147452A (ru) 2016-06-20
EP2841459A1 (en) 2015-03-04
KR20150008080A (ko) 2015-01-21

Similar Documents

Publication Publication Date Title
BR112014026744A2 (pt) anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, métodos para tratar uma condição, distúrbio ou doença, para modular um distúrbio ou condição e para produzir um anticorpo ou fragmento, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada
BR112015021618A2 (pt) métodos e composições para controle de ervas daninhas
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
CL2012003180A1 (es) Mezcla de plaguicidas; composicion plaguicisa que comprende dicha mezcla; metodo para controlar plagas de animales y/o mejorar la salud de las plantas; material de propagación vegetal; uso de la mezcla para controlar plagas en animales.
BR112017022526A2 (pt) uso de uma composição de tratamento capilar
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
BR112012004696B8 (pt) composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
PE20160949A1 (es) Cepa aislada de clonostachys rosea para uso como agente de control biologico
ECSP17061751A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017016759A2 (pt) recipiente de plástico pré-carregado, kit, uso do recipiente de plástico pré-carregado, método para o tratamento de uma doença ou condição, método para o tratamento cosmético da pele
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2019001541A1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros (divisional solicitud 201700896)
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
BR112016000563A2 (pt) Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica
BR112015023507A2 (pt) vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
BR112017009798A2 (pt) profármacos de hgh poliméricos
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
UY36405A (es) Formulaciones reguladoras/bioestimulantes del crecimiento de las plantas y de los cultivos y métodos para usarlas
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements